• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Clinical Characteristics of Patients with Coronavirus Disease (COVID-19): Preliminary Baseline Report of Japan COVID-19 Task For

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2021 Sep 30;S1201-9712(21)00775-X.
doi: 10.1016/j.ijid.2021.09.070. Online ahead of print.
Clinical Characteristics of Patients with Coronavirus Disease (COVID-19): Preliminary Baseline Report of Japan COVID-19 Task Force, a Nation-wide Consortium to Investigate Host Genetics of COVID-19


Hiromu Tanaka[SUP] 1 [/SUP], Ho Lee[SUP] 1 [/SUP], Atsuho Morita[SUP] 1 [/SUP], Ho Namkoong[SUP] 2 [/SUP], Shotaro Chubachi[SUP] 1 [/SUP], Hiroki Kabata[SUP] 1 [/SUP], Hirofumi Kamata[SUP] 1 [/SUP], Makoto Ishii[SUP] 1 [/SUP], Naoki Hasegawa[SUP] 2 [/SUP], Norihiro Harada[SUP] 3 [/SUP], Tetsuya Ueda[SUP] 4 [/SUP], Soichiro Ueda[SUP] 5 [/SUP], Takashi Ishiguro[SUP] 6 [/SUP], Ken Arimura[SUP] 7 [/SUP], Fukuki Saito[SUP] 8 [/SUP], Takashi Yoshiyama[SUP] 9 [/SUP], Yasushi Nakano[SUP] 10 [/SUP], Yoshikazu Mutoh[SUP] 11 [/SUP], Yusuke Suzuki[SUP] 12 [/SUP], Koji Murakami[SUP] 13 [/SUP], Yukinori Okada[SUP] 14 [/SUP], Ryuji Koike[SUP] 15 [/SUP], Yuko Kitagawa[SUP] 16 [/SUP], Katsushi Tokunaga[SUP] 17 [/SUP], Akinori Kimura[SUP] 18 [/SUP], Seiya Imoto[SUP] 19 [/SUP], Satoru Miyano[SUP] 20 [/SUP], Seishi Ogawa[SUP] 21 [/SUP], Takanori Kanai[SUP] 22 [/SUP], Koichi Fukunaga[SUP] 1 [/SUP], Japan COVID-19 Task Force



Affiliations

Abstract

Background and design: The coronavirus disease (COVID-19) pandemic is having a devastating effect worldwide. Host genome differences between populations may influence the severity of COVID-19. The Japan COVID-19 Task Force is conducting host genome analysis of hospitalized patients with COVID-19 from more than 70 institutions nationwide in Japan. This report describes the clinical characteristics of patients enrolled to date.
Results: The median (interquartile range) age of the 1674 patients included in the analysis was 59 (45-71) years, and more than half of the patients (66.2%) were male. Less than half of the patients (41.2%) had severe disease. The case fatality rate was 3.2%.
Conclusions: Since this is a hospital-based study, the number of severe cases was relatively high, but the case fatality rate was relatively low, when compared to that of other countries. In the future, we will continue to enroll patients and conduct genome analyses of patients with COVID-19.

Keywords: COVID-19; Clinical character; Host genetics; Japan; Pneumonia.
 
Back
Top Bottom